Clarus Therapeutics
Clarus Therapeutics is a publicly traded biopharmaceutical company (NASDAQ: CRXT) that develops and commercializes JATENZO, an FDA-approved oral testosterone replacement therapy for men with hypogonadism, distributed through pharmacy channels under prescription.
- Company typePublic
- Founded2003
- HeadquartersNorthbrook, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Clarus Therapeutics does
Clarus Therapeutics is a biopharmaceutical company that develops androgen-based medicines for men and women. Founded in 2003 and headquartered in Northbrook, Illinois, the company operates as a publicly traded entity on NASDAQ under the ticker CRXT, with a headcount of 11-50 employees.
The company's commercial product is JATENZO, an FDA-approved oral softgel capsule formulation of testosterone undecanoate indicated for testosterone replacement therapy in adult men with hypogonadism (low testosterone). The product is differentiated by its oral route of administration, offering an alternative to traditional injectable testosterone therapies. JATENZO is the only product in Clarus's commercial offering according to available source data, and represents the company's primary revenue-generating asset through prescription pharmaceutical sales.
Clarus commercializes JATENZO via a sales-led go-to-market motion targeting healthcare providers and patients, with the product distributed through traditional pharmacy and specialty pharmacy channels under prescription. The company has financed its operations and commercialization through multiple funding rounds totaling approximately $122 million since 2004, including a $15 million private placement in December 2021 and a $30 million public offering of stock and warrants in April 2022, both explicitly directed at JATENZO commercialization and working capital. The capital cadence and continued reliance on primary financing indicate the company is in an early commercial stage.
Clarus Therapeutics firmographics
Firmographics- Name
- Clarus Therapeutics
- Legal name
- Clarus Therapeutics Holdings, Inc.
- Website
- https://clarustherapeutics.com
- Company type
- Public
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Clarus Therapeutics is a publicly traded biopharmaceutical company (NASDAQ: CRXT) that develops and commercializes JATENZO, an FDA-approved oral testosterone replacement therapy for men with hypogonadism, distributed through pharmacy channels under prescription.
- Ownership category
- akta.pro rank
Clarus Therapeutics industry classification
Industry- Product category
- Men's Health Pharmaceuticals / Testosterone Replacement Therapy
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- akta.pro primary industry
- Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)
Keywords
Where Clarus Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Northbrook
- HQ country
- United States
- HQ region
- North America
Markets served
Clarus Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Marketing or Sales, Supply Chain, Personnel, Operations
Revenue model
- JATENZO Product Sales: Revenue generated from sales of JATENZO, an FDA-approved oral testosterone product for men with low testosterone. The company commercialized this product following FDA approval, with $15 million raised in December 2021 specifically to support commercialization activities.
Go-to-market motion1 record
Distribution channels1 record
Clarus Therapeutics product offering
Product offeringCore offering
Clarus Therapeutics develops and commercializes androgen-based prescription pharmaceuticals, with its primary product being JATENZO, an FDA-approved oral softgel capsule of testosterone undecanoate indicated for testosterone replacement therapy in adult men with hypogonadism. The company focuses on the U.S. commercialization of this single oral testosterone product as an alternative to traditional injectable testosterone therapies.
Product overview
Clarus Therapeutics is a pharmaceutical company that offers JATENZO, an oral testosterone product. The company focuses on the commercialization of this single product for treating hypogonadism in men.
Differentiator
Problem solved
Functional benefit
Brands
- JATENZO: Oral testosterone product for the treatment of hypogonadism in men.
Products and services
- JATENZO
Companies that use Clarus Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
Clarus Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Clarus Therapeutics partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights3 records
Clarus Therapeutics competitors and assessment
Company assessmentDirect peers
- Besins Healthcare: Besins licenses and markets AndroGel (testosterone gel) outside the U.S., operating in the same TRT category and androgen-replacement therapeutic area as Clarus.
- Marius Pharmaceuticals: Marius commercializes Kyzatrex, an oral testosterone undecanoate product for adult male hypogonadism — the closest direct head-to-head competitor to Clarus's JATENZO in the same product category and patient population.
- Tolmar Pharmaceuticals: Tolmar markets Xyosted (auto-injector testosterone enanthate) for hypogonadism and also co-developed TLANDO, placing it as a direct competitor to Clarus in the TRT replacement therapy category.
- Acerus Pharmaceuticals: Acerus markets Natesto, a nasal testosterone product for hypogonadism, competing with JATENZO in the non-injectable, non-topical TRT segment.
- Antares Pharma (now part of Halozyme): Antares developed TLANDO, another oral testosterone undecanoate product approved for hypogonadism, making it a direct same-mechanism competitor to JATENZO in the oral TRT category.
Broad incumbents
- AbbVie: AbbVie (via legacy Allergan) markets AndroGel, the leading topical testosterone gel for hypogonadism — a broad incumbent whose TRT franchise competes for the same prescriptions as JATENZO.
- Ferring Pharmaceuticals: Ferring is a reproductive-health and urology-focused pharmaceutical incumbent with adjacent hormone-replacement assets, making it a relevant comparator in the broader andrology/endocrine space Clarus addresses.
- Viatris: Viatris (formed from Mylan/Pfizer Upjohn) distributes generic and branded testosterone products including injectable testosterone enanthate and cypionate, competing in the same male hypogonadism prescription market as JATENZO.
- Endo International (Endo Pharmaceuticals): Endo markets Aveed (injectable testosterone undecanoate) and previously competed in TRT broadly, making it an established incumbent competing with Clarus in the same male hypogonadism market.
Emerging players
- Lipocine: Lipocine is developing oral testosterone products (LPCN 1144, Tlando) for liver-related and hypogonadism indications, making it an emerging competitor in the oral testosterone space relevant to Clarus.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Clarus Therapeutics social profiles
Digital presenceClarus Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Clarus Therapeutics leadership team
Management profileNumber of profiles
Profiles1 record
Clarus Therapeutics funding detail
Funding detailFunding overview
Funding rounds8 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Clarus Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Clarus Therapeutics
What does Clarus Therapeutics do?
Clarus Therapeutics develops and commercializes androgen-based prescription pharmaceuticals, with its primary product being JATENZO, an FDA-approved oral softgel capsule of testosterone undecanoate indicated for testosterone replacement therapy in adult men with hypogonadism. The company focuses on the U.S. commercialization of this single oral testosterone product as an alternative to traditional injectable testosterone therapies.
Is Clarus Therapeutics a public or private company?
Clarus Therapeutics is a public company. It is classified as public and is currently operating.
When was Clarus Therapeutics founded?
Clarus Therapeutics was founded in 2003. It employs 11 to 50 people.
Where is Clarus Therapeutics based?
Clarus Therapeutics is headquartered in Northbrook, United States, in the North America region.
How does Clarus Therapeutics make money?
One revenue line is on record: JATENZO Product Sales.
Who are Clarus Therapeutics's main competitors?
Direct peers on record are Besins Healthcare, Marius Pharmaceuticals, Tolmar Pharmaceuticals, Acerus Pharmaceuticals and Antares Pharma (now part of Halozyme). Broad incumbents are AbbVie, Ferring Pharmaceuticals, Viatris and Endo International (Endo Pharmaceuticals). Lipocine is listed as an emerging player.
Does Clarus Therapeutics have an API?
No public API is recorded for Clarus Therapeutics.
What industry is Clarus Therapeutics in?
Clarus Therapeutics's product category is Men's Health Pharmaceuticals / Testosterone Replacement Therapy. Its primary akta.pro industry code is HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 325412.